Compare HWKN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | RCUS |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | 674 |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | HWKN | RCUS |
|---|---|---|
| Price | $134.95 | $25.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $200.00 | $28.75 |
| AVG Volume (30 Days) | 147.6K | ★ 1.7M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 1.59 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $1,045,229,000.00 | $240,000,000.00 |
| Revenue This Year | $15.55 | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $98.30 | $6.50 |
| 52 Week High | $186.15 | $26.35 |
| Indicator | HWKN | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 76.68 |
| Support Level | $127.65 | $19.44 |
| Resistance Level | $132.48 | $26.32 |
| Average True Range (ATR) | 5.50 | 1.28 |
| MACD | 2.35 | 0.38 |
| Stochastic Oscillator | 93.13 | 84.34 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.